gavreto
roche registration gmbh - pralsetinib - karcinóm, pľúc bez malých buniek - antineoplastické činidlá - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.
gala 334 sl
adama - sl - picloram 67 g/l, + clopyralid 267 g/l, - herbicíd
sencor liquid
bayer ag - suspenzný koncentrát - metribuzin 600 g/l
adengo sc
bayer ag - tekutý dispergovateľný koncentrát - thiencarbazone-methyl 90 g/l; isoxaflutole 225 g/l; safener - cyprosulfamide 150 g/l
husar star
bayer ag - vodou dispergovateľný granulát - iodosulfuron-methyl-sodium 33 g/kg; thiencarbazone-methyl 25 g/kg; mefenpyr-diethy (safener) 150 g/kg
sencor liquid
bayer ag - suspenzný koncentrát - metribuzin 600 g/l
prístroj agfa curix 60
agfa healthcare n.v. septestraat 27 be2640 mortsel belgicko -
rtg film agfa acurix xp
agfa - gevaert, n.v., mortsel belgicko -
rtg film agfa curix duplicating
agfa healthcare n.v. septestraat 27 be2640 mortsel belgicko -
rtg film agfa curix duplicating
agfa healthcare n.v. septestraat 27 be2640 mortsel belgicko -